Malignant Neoplasm of Unknown Primary — Research

Malignant Neoplasm of Unknown Primary — Research · CancerIndex

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

pubmedComputed3 windows · counts computed by CancerIndex from PubMed E-utilities; the exact query is stored with each count.

Window	Period	Records (count)	Exact query	Computed	Source
All time	… → 2026-09-11	1,145	`("Malignant Neoplasm of Unknown Primary"[tiab] OR "Cancer of Unknown Primary"[tiab] OR "Cancer of Unknown Primary Site"[tiab] OR "cancer of unknown primary origin"[tiab] OR "Metastatic Malignant Neoplasm of Unknown Primary Origin"[tiab])`	2026-09-11	pubmed
Last 5 years	2021-01-01 → 2026-12-31	520	`("Malignant Neoplasm of Unknown Primary"[tiab] OR "Cancer of Unknown Primary"[tiab] OR "Cancer of Unknown Primary Site"[tiab] OR "cancer of unknown primary origin"[tiab] OR "Metastatic Malignant Neoplasm of Unknown Primary Origin"[tiab]) AND (2021/01/01:2026/12/31[dp])`	2026-09-11	pubmed
Last 12 months	2025-09-11 → 2026-09-11	95	`("Malignant Neoplasm of Unknown Primary"[tiab] OR "Cancer of Unknown Primary"[tiab] OR "Cancer of Unknown Primary Site"[tiab] OR "cancer of unknown primary origin"[tiab] OR "Metastatic Malignant Neoplasm of Unknown Primary Origin"[tiab]) AND (2025/09/11:2026/09/11[dp])`	2026-09-11	pubmed

Data updated 20 days agoSource updated unknownsource: pubmed E-utilities

Literature

Linked publications (486)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedPublishedShowing 1–25 of 486 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
· N Engl J Med · 2019 · PMID 31157963 · validated civic_curation pubmed
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
· N Engl J Med · 2021 · PMID 34081848 · validated civic_curation pubmed
Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer.
· N Engl J Med · 2023 · PMID 37870969 · validated civic_curation pubmed
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.